
Clinical Laserthermia Systems Investor Relations Material
Latest events

Q1 2025
16 May, 2025

Q4 2024
21 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Clinical Laserthermia Systems
Access all reports
Clinical Laserthermia Systems AB is a Swedish medical technology company focused on developing minimally invasive laser-based treatment systems for cancer and neurosurgery. The company’s flagship product is the TRANBERG Thermal Therapy System, which is designed for precision laser ablation of solid tumors. This system enables high-precision, image-guided treatments for conditions such as prostate cancer and brain lesions. CLS is also advancing imILT (immunostimulating interstitial laser thermotherapy), which combines laser ablation with immune system stimulation to treat various types of tumors, including those in the liver, lungs, and pancreas. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
CLS
Country
🇸🇪 Sweden